Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

β-lactam

  • Synergistic Interactions of Indole-2-Carboxamides and β-Lactam Antibiotics against <span class="named-content genus-species" id="named-content-1">Mycobacterium abscessus</span>
    Mechanisms of Action: Physiological Effects
    Synergistic Interactions of Indole-2-Carboxamides and β-Lactam Antibiotics against Mycobacterium abscessus

    New drugs or therapeutic combinations are urgently needed against Mycobacterium abscessus. Previously, we demonstrated the potent activity of indole-2-carboxamides 6 and 12 against M. abscessus. We show here that these compounds act synergistically with imipenem and cefoxitin in vitro and...

    Clément Raynaud, Wassim Daher, Françoise Roquet-Banères, Matt D. Johansen, Jozef Stec, Oluseye K. Onajole, Diane Ordway, Alan P. Kozikowski, Laurent Kremer
  • Unorthodox Parenteral β-Lactam and β-Lactamase Inhibitor Combinations: Flouting Antimicrobial Stewardship and Compromising Patient Care
    Editor's Pick Commentary
    Unorthodox Parenteral β-Lactam and β-Lactamase Inhibitor Combinations: Flouting Antimicrobial Stewardship and Compromising Patient Care

    In India and China, indigenous drug manufacturers market arbitrarily combined parenteral β-lactam and β-lactamase inhibitors (BL-BLIs). In these fixed-dose combinations, sulbactam or tazobactam is indiscriminately combined with parenteral cephalosporins, with BLI doses kept in ratios similar to those for the approved BL-BLIs. Such combinations have been introduced into clinical practice without mandatory drug development studies...

    Snehal Palwe, Balaji Veeraraghavan, Hariharan Periasamy, Kshama Khobragade, Arun S. Kharat
  • Structural Insights into the Inhibition of the Extended-Spectrum β-Lactamase PER-2 by Avibactam
    Mechanisms of Resistance
    Structural Insights into the Inhibition of the Extended-Spectrum β-Lactamase PER-2 by Avibactam

    The diazabicyclooctane (DBO) avibactam (AVI) reversibly inactivates most serine-β-lactamases.

    Melina Ruggiero, Krisztina M. Papp-Wallace, Florencia Brunetti, Melissa D. Barnes, Robert A. Bonomo, Gabriel Gutkind, Sebastián Klinke, Pablo Power
  • Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant <span class="named-content genus-species" id="named-content-1">Klebsiella pneumoniae</span> Producing KPC
    Mechanisms of Resistance
    Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC

    Carbapenem-resistant Enterobacteriaceae (CRE) are resistant to most antibiotics, making CRE infections extremely difficult to treat with available agents. Klebsiella pneumoniae carbapenemases (KPC-2 and KPC-3) are predominant carbapenemases in CRE in the United States. Nacubactam is a bridged...

    Melissa D. Barnes, Magdalena A. Taracila, Caryn E. Good, Saralee Bajaksouzian, Laura J. Rojas, David van Duin, Barry N. Kreiswirth, Michael R. Jacobs, Andreas Haldimann, Krisztina M. Papp-Wallace, Robert A. Bonomo
  • Open Access
    Bedaquiline Eliminates Bactericidal Activity of β-Lactams against <span class="named-content genus-species" id="named-content-1">Mycobacterium abscessus</span>
    Editor's Pick Mechanisms of Action: Physiological Effects
    Bedaquiline Eliminates Bactericidal Activity of β-Lactams against Mycobacterium abscessus

    The β-lactams imipenem and cefoxitin are used for the treatment of Mycobacterium abscessus lung infections. Here, we show that these cell wall synthesis inhibitors trigger a lethal bacterial ATP burst by increasing oxidative phosphorylation. Cotreatment of M. abscessus with the antimycobacterial ATP...

    Marissa Lindman, Thomas Dick
  • Negative Impact of Carbapenem Methylation on the Reactivity of β-Lactams for Cysteine Acylation as Revealed by Quantum Calculations and Kinetic Analyses
    Chemistry; Biosynthesis
    Negative Impact of Carbapenem Methylation on the Reactivity of β-Lactams for Cysteine Acylation as Revealed by Quantum Calculations and Kinetic Analyses

    The Enterococcus faecium l,d-transpeptidase (Ldtfm) mediates resistance to most β-lactam antibiotics in this bacterium by replacing classical peptidoglycan polymerases. The catalytic Cys of Ldtfm is rapidly acylated by β-lactams belonging to the carbapenem class but not by penams or cephems.

    ...
    Nicholus Bhattacharjee, Sébastien Triboulet, Vincent Dubée, Matthieu Fonvielle, Zainab Edoo, Jean-Emmanuel Hugonnet, Mélanie Ethève-Quelquejeu, Jean-Pierre Simorre, Martin J. Field, Michel Arthur, Catherine M. Bougault
  • Efficacy of Human-Simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine β-Lactamase-Producing <em>Enterobacteriaceae</em> in the Neutropenic Murine Lung Infection Model
    Experimental Therapeutics
    Efficacy of Human-Simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine β-Lactamase-Producing Enterobacteriaceae in the Neutropenic Murine Lung Infection Model

    Nacubactam is a novel, broad-spectrum, β-lactamase inhibitor that is currently under development as combination therapy with meropenem. This study evaluated the efficacy of human-simulated epithelial lining fluid (ELF) exposures of meropenem, nacubactam, and the combination of meropenem and nacubactam against class A serine carbapenemase-producing ...

    Tomefa E. Asempa, Ana Motos, Kamilia Abdelraouf, Caterina Bissantz, Claudia Zampaloni, David P. Nicolau
  • AmpI Functions as an Iron Exporter To Alleviate β-Lactam-Mediated Reactive Oxygen Species Stress in <em>Stenotrophomonas maltophilia</em>
    Mechanisms of Resistance
    AmpI Functions as an Iron Exporter To Alleviate β-Lactam-Mediated Reactive Oxygen Species Stress in Stenotrophomonas maltophilia

    Stenotrophomonas maltophilia is an organism with a remarkable capacity for drug resistance with several antibiotic resistance determinants in its genome. S. maltophilia genome codes for L1 and L2, responsible for intrinsic β-lactam resistance.

    Yi-Wei Huang, Hsin-Hui Huang, Kai-Hung Huang, Wei-Chien Chen, Yi-Tsung Lin, Cheng-Chih Hsu, Tsuey-Ching Yang
  • Adjuvant β-Lactam Therapy Combined with Vancomycin for Methicillin-Resistant <em>Staphylococcus aureus</em> Bacteremia: Does β-Lactam Class Matter?
    Clinical Therapeutics
    Adjuvant β-Lactam Therapy Combined with Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia: Does β-Lactam Class Matter?

    We analyzed the impact of vancomycin (VAN) combined with adjuvant β-lactam therapy (Combo) on persistent (≥5 days) methicillin-resistant Staphylococcus aureus bacteremia versus VAN alone by using pooled data from two previously published observational studies (n = 156). Combo was inversely associated with persistent bacteremia (adjusted odds ratio, 0.460; 95...

    Thomas J. Dilworth, Anthony M. Casapao, Omar M. Ibrahim, David M. Jacobs, Dana R. Bowers, Nicholas D. Beyda, Renee-Claude Mercier
  • Past and Present Perspectives on β-Lactamases
    Minireview
    Past and Present Perspectives on β-Lactamases

    β-Lactamases, the major resistance determinant for β-lactam antibiotics in Gram-negative bacteria, are ancient enzymes whose origins can be traced back millions of years ago. These well-studied enzymes, currently numbering almost 2,800 unique proteins, initially emerged from environmental sources, most likely to protect a producing bacterium from attack by naturally occurring β-lactams.

    Karen Bush

Pages

  • Next
  • 1
  • 2
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596